Valuation : Fulgent Genetics, Inc.

Market Cap 554M 477M 452M 409M 768M 52.89B 772M 5.36B 2.06B 26.91B 2.08B 2.03B 85.03B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 554M 477M 452M 409M 768M 52.89B 772M 5.36B 2.06B 26.91B 2.08B 2.03B 85.03B EV / Sales 2026 *
1.67x
EV / Sales 2027 * 1.45x
Free-Float
48.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week+2.53%
Current month+4.44%
1 month+6.47%
3 months+7.72%
6 months+40.78%
Current year-22.99%
1 week 19.44
Extreme 19.44
20.36
1 month 18.28
Extreme 18.28
20.52
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
31.04
5 years 13.46
Extreme 13.46
109.55
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 03/05/2022
Chief Executive Officer 70 13/05/2016
Director of Finance/CFO 58 01/01/2016
Director TitleAgeSince
Chairman 70 01/09/2016
Director/Board Member 76 01/08/2019
Director/Board Member 57 01/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Founder

-2,127 0.0069%
9/2/26 A Sell

Chief Technology Officer

-1,673 0.0055%
9/1/26 A Tax

Chief Financial Officer

-2,087 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+2.53%-9.08%-34.13% 554M
+0.69%+0.03%+88.87%+501.34% 47.01B
+0.02%-6.28%+9.52%+51.72% 24.89B
-1.91%-1.55%-16.30%-38.91% 6.86B
+0.50%+0.78%+0.75%+152.58% 5.85B
-0.40%-0.84%+18.44%+72.18% 3.35B
+3.27%+0.36%-31.45%+1,709.22% 2.5B
-1.90%-0.63%+107.07%+24.33% 2.26B
+13.65%+5.26%+36.09%+46.92% 2.24B
-0.73%-2.52%-19.23%-56.73% 1.78B
Average +1.35%-0.17%+18.47%+242.85% 9.73B
Weighted average by Cap. +0.54%-1.04%+47.01%+308.78%

Financials

2026 *2027 *
Net sales 332M 286M 271M 245M 460M 31.69B 462M 3.21B 1.24B 16.12B 1.25B 1.22B 50.94B 383M 330M 312M 283M 531M 36.56B 534M 3.71B 1.43B 18.6B 1.44B 1.41B 58.78B
Net income -112M -96.5M -91.37M -82.82M -155M -10.7B -156M -1.09B -417M -5.44B -421M -411M -17.2B -79M -68.07M -64.45M -58.42M -110M -7.55B -110M -765M -294M -3.84B -297M -290M -12.13B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
11/09/26 $20.25 +0.65% 161,005
10/09/26 $20.12 +1.36% 337,288
09/09/26 $19.85 -1.73% 369,944
08/09/26 $20.20 +2.38% 374,990
04/09/26 $19.73 +0.41% 224,999
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20.12USD
Average target price
19.00USD
Spread / Average Target
-5.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLGT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!